Key Dates

Related Announcements

• April 12, 2022 - Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional). See NOFO PAR-22-131

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct Other Submission Requirements and Information in Section IV. Application and Submission Information of PAR-22-131, Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional).

Effective immediately, this Notice also applies to forthcoming Application Due Dates, beginning with February 05, 2024.

The following section has been corrected.

Section IV. Application and Submission Information, 7. Other Submission Requirements and Information

Corrected to read (by addition of text in bold italics):

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential fieldof the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the unique entity identifier (DUNS number or UEI as required) provided on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Requests of $500,000 or more for direct costs in any year

Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

All other aspects of PAR-22-131 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

For questions about applications on the topic that are more focused on the prevention, intervention and early detection of cancer and pre cancerous lesions, contact:

Sudhir Srivastava, Ph.D., MPH
National Cancer Institute (NCI)
Telephone: 240-276-7028
Email: srivasts@mail.nih.gov

Richard Mazurchuk, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7126
Email: mazurchukrv@mail.nih.gov

Guillermo Marquez, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7035
Email: marquezg@mail.nih.gov

For questions about applications on the topic that are more focused on cancer diagnosis, prognosis, and treatment, contact:

Huiming Zhang, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5979
Email: zhanghui@mail.nih.gov

Peer Review Contact(s)

Yuanna Cheng, Ph.D.
Center for Scientific Review (CSR)
Telephone: 301-435-1195
E-mail: chengy5@mail.nih.gov

Financial/Grants Management Contact(s)

Amy R. Bartosch
National Cancer Institute (NCI)
Telephone: 240-276-6912
Email: amy.bartosch@nih.gov